MiR-181a targets STING to drive PARP inhibitor resistance in BRCA- mutated triple-negative breast cancer and ovarian cancer

BACKGROUND: Poly (ADP-ribose) polymerase inhibitors (PARPi) are approved for the treatment of BRCA-mutated breast cancer (BC), including triple-negative BC (TNBC) and ovarian cancer (OvCa). A key challenge is to identify the factors associated with PARPi resistance; although, previous studies sugges...

Descripción completa

Detalles Bibliográficos
Autores principales: Bustos, Matias A., Yokoe, Takamichi, Shoji, Yoshiaki, Kobayashi, Yuta, Mizuno, Shodai, Murakami, Tomohiro, Zhang, Xiaoqing, Sekhar, Sreeja C., Kim, SooMin, Ryu, Suyeon, Knarr, Matthew, Vasilev, Steven A., DiFeo, Analisa, Drapkin, Ronny, Hoon, Dave S. B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10626784/
https://www.ncbi.nlm.nih.gov/pubmed/37932806
http://dx.doi.org/10.1186/s13578-023-01151-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10626784/
https://www.ncbi.nlm.nih.gov/pubmed/37932806
http://dx.doi.org/10.1186/s13578-023-01151-y

Ejemplares similares